EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The combination of the HDAC1 inhibitor SAHA and doxorubicin has synergic efficacy in triple negative breast cancer in vivo

Yuheng Pang, Runze Shi, Liujia Chan, Yu Lu, Di Zhu, Tong Liu, Meisi Yan, Yuji Wang, Wenjing Wang

Pharmacological Research · 2023-10 · 196 · 106926

DOI: 10.1016/j.phrs.2023.106926 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacological Research, 2023-10. Verfasst von Yuheng Pang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Tumor Hospital of Harbin Medical University, Harbin, Heilongjiang, PR China; NHC Key Laboratory of Cell Transplantation…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Doxorubicin, Vorinostat, Histone Deacetylase Inhibitors. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsDoxorubicinVorinostatHistone Deacetylase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHistone Deacetylase 1Antineoplastic AgentsAnimalsFemaleHumansDrug SynergismCell Line, TumorCell ProliferationMiceMice, Inbred BALB CXenograft Model Antitumor AssaysTumor MicroenvironmentMice, Nude

Stichwörter der Autor:innen

Cancer stem cellsDoxorubicinTriple negative breast cancerTumor immune microenvironmentVorinostat

Substanzen

DoxorubicinVorinostatHistone Deacetylase InhibitorsHistone Deacetylase 1Antineoplastic AgentsHDAC1 protein, human

Autor:innen und Institutionen

  • Department of Breast Surgery, Tumor Hospital of Harbin Medical University, Harbin, Heilongjiang, PR China; NHC Key Laboratory of Cell Transplantation, The First Affiliated Hospital of Harbin Medical University, Harbin,…
  • Department of Breast Surgery, Tumor Hospital of Harbin Medical University, Harbin, Heilongjiang, PR China.
  • College of Pharmaceutical Sciences, Capital Medical University, Beijing, PR China.
  • Pathology Teaching and Research Section, Basic Medical College of Harbin Medical University, Harbin, Heilongjiang, PR China; NHC Key Laboratory of Cell Transplantation, The First Affiliated Hospital of Harbin Medical Un…
  • College of Pharmaceutical Sciences, Capital Medical University, Beijing, PR China. Electronic address: wangyuji@ccmu.edu.cn.
  • Beijing Institute of Hepatology, Beijing YouAn Hospital, Capital Medical University, Beijing, PR China. Electronic address: wangwenjing85321@ccmu.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Pang, Y., Shi, R., Chan, L., Lu, Y., Zhu, D., Liu, T., Yan, M., Wang, Y., & Wang, W. (2023). The combination of the HDAC1 inhibitor SAHA and doxorubicin has synergic efficacy in triple negative breast cancer in vivo. Pharmacological Research, 196, 106926. https://doi.org/10.1016/j.phrs.2023.106926

Vancouver

Pang Y, Shi R, Chan L, Lu Y, Zhu D, Liu T, et al. The combination of the HDAC1 inhibitor SAHA and doxorubicin has synergic efficacy in triple negative breast cancer in vivo. Pharmacological Research. 2023;196:106926. doi:10.1016/j.phrs.2023.106926

BibTeX
@article{Pang2023,
  author = {Pang, Yuheng and Shi, Runze and Chan, Liujia and Lu, Yu and Zhu, Di and Liu, Tong and Yan, Meisi and Wang, Yuji and Wang, Wenjing},
  title = {The combination of the HDAC1 inhibitor SAHA and doxorubicin has synergic efficacy in triple negative breast cancer in vivo},
  journal = {Pharmacological Research},
  year = {2023},
  volume = {196},
  pages = {106926},
  doi = {10.1016/j.phrs.2023.106926}
}
Kostenlos starten →